Condition: Hyperlipidemias · Sponsor: Shandong Suncadia Medicine Co., Ltd.
The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.
This description comes directly from the study's public registry record.
Ying Wang, PhD · +86-0518-81220121 · ying.wang.yw30@hengrui.com
Always discuss trial participation with your own doctor first.
| Sichuan Provincial People's Hospital | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07322016